What is Tetanus Immune Globulin (TIG)
Tetanus immune globulin (TIG), human, is a parenteral preparation of immunoglobulins prepared from plasma of adults hyperimmunized with tetanus toxoid.
TIG contains tetanus antibodies that neutralize the exotoxin produced by Clostridium tetani, thereby providing passive immunity to tetanus toxin.
Tetanus immune globulin (TIG) is used primarily for prophylaxis of tetanus infection in patients with traumatic injuries.
Patients who have not completed a primary vaccination series with tetanus toxoid may require both tetanus toxoid and passive immunization with TIG at the time of wound cleansing and debridement.
Previously, tetanus antitoxin derived from either horse or bovine was used to provide passive immunity against tetanus. Human TIG is now the agent of choice when passive immunization against tetanus is required.
Human TIG provides longer protection and induces fewer severe allergic reactions than the animal-derived tetanus antitoxins.
TIG undergoes solvent and detergent treatment to inactivate blood borne virus such as HIV, hepatitis B, and hepatitis C.
TIG is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain.
Passive immunization with TIG may be given concurrently with tetanus toxoid in patients who must receive immediate protection against tetanus and in whom concomitant active immunization is desired.
TIG is also indicated for the active treatment of tetanus infection, although efficacy data supporting this indication are limited. The FDA originally approved tetanus immune globulin in October 1957.
- HyperTET S/D
- tetanus prophylaxis
- anaphylactic shock
- injection site reaction
- nephrotic syndrome
- laboratory monitoring not necessary
- IgA deficiency
- intravenous administration
- Measles Virus; Mumps Virus; Rubella Virus; Varicella Virus Vaccine, Live
- Measles/Mumps/Rubella Vaccines, MMR
- Rotavirus Vaccine
- Rubella Virus Vaccine Live
- Varicella-Zoster Virus Vaccine, Live